Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast Long-Term Extension in Pediatric Behçet's Disease and Juvenile Psoriatic Arthritis
NCT05767047Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Mar 2023
- Primary completion
- Mar 2036
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of apremilast in Behçet's disease (BD), juvenile psoriatic arthritis (JPsA), sponsored by Amgen. Started Mar 2023; status: recruiting.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT05767047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767047.